Table 3 Clinical features of COVID-19 in our patient cohort

COVID-19 infection

Asymptomatic

675

17.8

Mild

658

17.3

Severe

1736

45.7

Critical

689

18.1

Unknown

43

1.1

COVID-19 test sample^a

BAL

60

1.6

SARS-CoV-2 nasopharyngeal swab

3700

97.3

SARS-CoV-2 serology

86

2.3

Reason for COVID-19 test^a

Pulmonary symptoms

1454

38.3

Pulmonary + extrapulmonary symptoms

831

21.9

Extrapulmonary symptoms

742

19.5

Screening

727

19.1

Unknown

47

1.2

Neutrophils level at COVID-19 diagnosis^b

≤ 0.5 × 10⁹/mm³

280

7.4

0.501–0.999 × 10⁹/mm³

217

5.7

 ≥ 1 × 10⁹/mm³

2738

72.0

Lymphocytes level at COVID-19 diagnosis^b

 ≤  0.2 × 10⁹/mm³

344

9.1

0.201–0.499 × 10⁹/mm³

538

14.2

 ≥ 0.5 × 10⁹/mm³

2367

62.3

Stay during COVID-19

Admitted to hospital

2778

73.1

Length of hospital stay, median (IQR) [range]

15 (8–27), [1–235]

–

ICU

689

18.1

Length of ICU stay, median (IQR) [range]

11 (5–20), [1–111]

–

 Invasive MV

449

11.8

 Non-invasive MV

221

5.8

Clinical outcome of COVID-19

Death

1185

31.2

Observation time, median (IQR) [range]

89 (21–172), [0–436]

–

Reason for death^a

Not related to COVID-19

125

3.3

Contributable by COVID-19

155

4.1

Attributable to COVID-19

843

22.2

Attributable to HM

328

8.6

Death due to other reasons

123

3.2

Death due to unknown reasons

78

2.1